Valsartan/sacubitril reduces mortality more than enalapril 10 mg twice daily in patients with heart failure (PARADIGM-HF)

Valsartan/sacubitril reduces mortality more than enalapril 10 mg twice daily in patients with heart failure (PARADIGM-HF) is a topic covered in the EE+ POEM Archive.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central